1. Home
  2. REZI vs ACAD Comparison

REZI vs ACAD Comparison

Compare REZI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Resideo Technologies Inc.

REZI

Resideo Technologies Inc.

N/A

Current Price

$19.63

Market Cap

4.7B

Sector

Industrials

ML Signal

N/A

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$29.11

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REZI
ACAD
Founded
2018
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
4.3B
IPO Year
2018
2000

Fundamental Metrics

Financial Performance
Metric
REZI
ACAD
Price
$19.63
$29.11
Analyst Decision
Buy
Buy
Analyst Count
3
22
Target Price
$39.67
$30.55
AVG Volume (30 Days)
2.6M
1.7M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
0.68
0.20
Revenue
$7,472,000,000.00
$726,437,000.00
Revenue This Year
$6.81
$18.80
Revenue Next Year
$3.62
$11.70
P/E Ratio
$29.38
$148.65
Revenue Growth
10.52
40.45
52 Week Low
$18.96
$19.69
52 Week High
$45.29
$30.96

Technical Indicators

Market Signals
Indicator
REZI
ACAD
Relative Strength Index (RSI) 30.95 57.27
Support Level N/A $25.00
Resistance Level $33.09 $30.96
Average True Range (ATR) 1.13 0.87
MACD 0.02 -0.12
Stochastic Oscillator 13.90 47.55

Price Performance

Historical Comparison
REZI
ACAD

About REZI Resideo Technologies Inc.

Resideo Technologies Inc is a manufacturer and developer of technology-driven products and components that provide critical comfort, energy management, and safety and security solutions. The company has two reportable segments; Products and Solutions segment offers temperature and humidity control, energy products and solutions, water and air solutions, smoke and carbon monoxide detection home safety products, security panels, sensors, peripherals, wire and cable, communications devices, video cameras, other home-related lifestyle convenience solutions; and ADI Global Distribution segment includes wholesale distributor of low-voltage security products including access control, fire detection, security, and video products. It derives majority of its revenue from the United States.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: